

CURRICULUM VITAE
Marco Cassone, MD, PhD

POSIZIONE ATTUALE

Professore Associato
Settore scientifico disciplinare MED/07
Saint Camillus International University of Health Sciences, Rome

PERCORSO ACCADEMICO E ALTRE POSIZIONI ED ESPERIENZE LAVORATIVE

1997 Laurea in Medicina e Chirurgia con lode, Università di Roma “La Sapienza”

1994-1997: Interno, III^a Clinical Medica, Policlinico Umberto I, Università degli Studi di Roma “la Sapienza”,
Direttore: Prof. Pietro Serra. Supervisor: Prof. Pietro Serra, Prof. Camillo Brandimarte, Dr. Mario Venditti.

1997-2002: Specializzazione, Medicina Interna, III^a Clinical Medica, Policlinico Umberto I, Università degli
Studi di Roma “la Sapienza”, Direttore: Prof. Pietro Serra. Supervisor: Prof. Pietro Serra, Prof. Camillo
Brandimarte, Dr. Mario Venditti, Dr. Paolo Palange, Dr. Claudio Santini.

2003-2005: Dottorato di Ricerca in Biotecnologie, Policlinico Universitario “Le Scotte”, Università di Siena.
Supervisor: Prof. Gianni Pozzi, Prof. Marco Oggioni.

2006-2010: Post-Doctoral Fellow, Temple University, Philadelphia, PA. Supervisor: Prof. Laszlo Otvos.

2010-2012: Post-Doctoral Fellow, University of Pennsylvania, and The Children’s Hospital of Philadelphia,
Philadelphia, PA. Supervisor: Prof. Michael Seibert.

2012 Abilitazione Nazionale, Professore Associato (ASN – MIUR MED07)

2014-2016: Research Associate, Division of Geriatrics and Palliative Care Medicine, Department of Internal
Medicine, Michigan Medicine. University of Michigan, Ann Arbor, MI. Supervisor: Prof. Lona Mody.

2016-2020: Research Investigator, Division of Geriatrics and Palliative Care Medicine, Department of
Internal Medicine, Michigan Medicine. University of Michigan, Ann Arbor, MI.

2020 Abilitazione Nazionale, Professore Ordinario (ASN – MIUR MED07, Microbiologia Clinica)

2020-attuale: Research Assistant Professor, Division of Geriatrics and Palliative Care Medicine, Department
of Internal Medicine, Michigan Medicine. University of Michigan, Ann Arbor, MI.

2025-attuale: Commissario valutazione Progetti di Ricerca, National Institutes of Health, Sezione
“Anti-Infective Resistance and Targets” (AIRT).

CURRICULUM VITAE
Marco Cassone, MD, PhD

FONDI DI RICERCA (ultimi 5 anni)

HUM00243293 University of Michigan.

Evaluation of Quality-of-Life Improvements Using UroShield Device.

PI: Mody

2024 – 2025

NIH P30 AG024824: Claude D. Pepper Older Americans Independence Center

PI: Yung

2020 – 2025

Department of Veterans Affairs CSR&D VA Merit CSRD EPID-001-19S: Patient Movement and Impact in Multi-Drug Resistant Organism (MDRO) Transmission.

PI: Mody

2021 - 2025

University of Michigan Office of Research OVRP Pandemic Relief Funding Award

PI: Cassone

2022 - 2024

CDC F068230: Safety and Healthcare Epidemiology Prevention Research Development (SHEPherD): Nursing Home Public Health Response Network

PI: Mody

2022 – 2024

AHRQ R01 HS025451: Enhancing Patient Safety by Preventing Urinary Tract Infection in Post-Acute Care.

PI: Mody

08/2017-05/2022

University of Michigan Older Americans Independence Center (OAIC): Research Education Core (REC) Scholarship

PI: Cassone

2018 - 2020

ATTIVITA' SCIENTIFICA

- Sintesi, studi di structure–activity relationships (SAR) e sviluppo preclinico di derivative di peptidi antimicrobici naturali. Caratterizzazione di profilo di sicurezza, efficacia nei confronti di patogeni di rilevanza clinica e valutazione del loro indice terapeutico come singolo prodotto terapeutico e in combinazione sinergica con antibiotici tradizionali *in vitro* and *in vivo*.
- Ricerca sulla regolazione del fenomeno della “competenza” in *Streptococcus pneumoniae*, e scoperte riguardo al ruolo della competenza nel mantenimento della virulenza e della fitness in risposta al carico di mutazioni presenti nella cellula batterica, oltre che al ruolo di specifiche proteasi di membrana (HtrA proteasi) nell’inibizione della competenza in caso di basso carico di mutazioni.

CURRICULUM VITAE

Marco Cassone, MD, PhD

- Ricerca clinica in prevenzione delle infezioni, sorveglianza attiva ed epidemiologia di microrganismi di alto impatto clinico in scenari clinici ospedalieri, ambulatoriali, e di lungodegenza.
- Studi clinici longitudinale osservazionali e di intervento sulla persistenza e trasmissibilita' di organismi multiresistenti ad antibiotici in pazienti ricoverati in case di cura e riabilitazione, e nell'ambiente circostante i pazienti.
- Sviluppo e validazione di tecnologie di ibridazione molecolare basate su DNA microarrays per identificazione in formato multiplex di determinanti genetici di resistenza agli antibiotici e caratterizzazione di profili di trascrizione e della struttura dei relative operoni genetici accessori.
- Investigazioni di tecniche, sito corporeo ottimale, ed utilita' clinica della sorveglianza attiva di pazienti e del loro ambiente prossimo al fine di quantificare probabilita' e modalita' di colonizzazione e rischio clinico di eventi avversi nel paziente. Sviluppo e aggiornamento di linee guida ufficiali Istituzionali e di rilevanti Societa' Scientifiche con finalita' di aggiornamento professionale e di messa a punto di pratiche di sorveglianza e prevenzione anti-infettiva.
- Next generation whole-genome sequencing (WGS) di *Staphylococcus aureus* meticillino-resistente ed enterococchi resistenti alla vancomicina, e determinazione della loro prevalenza e trasmissione.
- Tipizzazione molecolare "High throughput" per investigazioni cliniche di epidemie locali (*Saccharomyces boulardii*) e regionali (*S. aureus* meticillino-resistente), e scoperta di nuovi cloni e/o meccanismi di trasmissione e propagazione epidemica.
- Studi di etero-resistenza agli antibiotici e di formazione di biofilm in campioni clinici.
- Sviluppo clinico di glicopeptidi agonisti del recettore della leptina e loro azioni sul regolamento del metabolismo, peso corporeo e fertilita' in modelli animali.
- Ricerca clinica in strategie di trattamento *ad-hoc* per presentazioni cliniche non comuni di infezioni da organismi antibiotico-resistenti, e sviluppo di tecniche di laboratorio in grado di valutare e predire la loro efficacia terapeutica per ogni specifico paziente.

PARAMETERI BIBLIOMETRICI

H Index (Scopus): 25
Citationi: (Scopus): 2131

H Index (Web of Science): 23
Citationi: (Web of Science): 1747

POSITIONI IN COMITATI EDITORIALI E REVISIONE DI PUBBLICAZIONI

Comitati editoriali

2020-presente: Frontiers in Public Health

2020-presente: Frontiers in Medicine

2010-2015: Infection and drug resistance

Revisione di manoscritti

- American Journal of Infection Control
- Antimicrobial Resistance and Infection Control

CURRICULUM VITAE
Marco Cassone, MD, PhD

- Biochimica et Biophysica Acta
- Bioessays
- BMC Genomics
- BMC Microbiology
- Cancer
- Cancer Letters
- Cancer Research
- Clinical Microbiology and Infection
- Clinical Microbiology Reviews
- Clinical Infectious Diseases
- Comparative Biochemistry and Physiology
- Current Signal Transduction Therapy
- Epidemiology and Infection
- Expert Review of Anti-Infective Therapy
- Gut Pathogens
- Heliyon (Cell Press)
- Infection Control and Hospital Epidemiology
- Infection and drug resistance
- International Journal of Cancer
- JAMA Network Open
- Journal of Cellular Physiology
- Journal of Infection
- Journal of Medicinal Chemistry
- Journal of Peptide Science
- Lancet Oncology
- Lancet Microbe
- Lancet Regional Health – Europe
- Medical Microbiology and immunology
- Microbiology Spectrum
- Molecular Cancer Therapeutics
- Molecular Microbiology
- mSphere
- PLOS One
- Protein and Peptide Letters
- Scientific Reports

PARTECIPAZIONE IN ORDINI PROFESSIONALI E SOCIETA' SCIENTIFICHE

Ordine dei Medici di Roma

American Society of Microbiology.

European Society of Clinical Microbiology and Infectious Diseases.

American Chemical Society

Society of Healthcare Epidemiology of America

CURRICULUM VITAE
Marco Cassone, MD, PhD

COLLABORAZIONI DI RICERCA INTERNATIONALI

Svizzera

Professor Hugo Sax e Dr. Aline Wolfsberger, University of Zurich Medical School, Zurich, Switzerland.

Wolfsberger A, Mang N, **Cassone M**, Gontjes K, Gibson K, Sax H, Mody L. Short-term environmental contamination with MRSA explained by in-room activity of MRSA-colonised patients. ECCMID 2020, Paris, France. Final results published in Infect Control Hosp Epidemiol (2022). 43(9):1147-54.

Ungheria

Professor Ferencz Rozgonyi, Semmelweis University, Budapest, Hungary.

M. Cassone, F. Rozgonyi, D. Szabo, B. Kocsis, P. Vogiatzi, L. Otvos, Jr. Study of in vivo Efficacy and Resistance Induction Potential of the Proline-rich Antimicrobial Peptide Dimer A3-APO and its Single Chain Metabolite. 109TH ASM Meeting, 2009, Philadelphia, PA. Final results published in multiple journals (see bibliography)

Australia

Professor John D. Wade, The Florey Institute, Parkville, Victoria, Australia.

Cassone M, Vogiatzi P, Wade JD, Rozgonyi F, Szabo D, Kocsis B, Otvos L Jr. The Proline-Rich antimicrobial peptide dimer A3-APO and its single chain in vivo metabolite represent a new paradigm in microbiology, pharmacology and drug development. 30th European Peptide Symposium (EPS), 2008, Helsinki, Finland. Final results published in multiple journals (see bibliography)

Germania

Professor Ralf Hoffmann e Dr. Daniel Knappe, University of Leipzig, Germany.

Knappe, D., **Cassone, M.**, Nollmann, F.I., Otvos Jr., L., Hoffmann, R. Hydroxyproline substitutions stabilize non-glycosylated drosocin against serum proteases without challenging its antibacterial activity. Protein and Peptide Letters (2014). 21 (4), pp. 321-329.

Hong Kong

Professor Vincent C Cheng, The University of Hong Kong, Hong Kong, China.

Cassone, M., Mantey, J., Perri, MB., Gibson, KE., Lansing, BJ., McNamara, SE., Patel, PK., Cheng, VCC., Walters, MS., Stone, ND., Zervos, M., Mody, L. Environmental panels as a proxy for nursing facility patients with MRSA and VRE colonization. Clinical Infectious Diseases (2018). 67 (6), pp 861-8.

CURRICULUM VITAE
Marco Cassone, MD, PhD

ESPERIENZA DIDATTICA E PEDAGOGICA

- 2002** Assistant Lecturer, Malattie Infettive (Prof. Pietro Serra). Facolta' di Medicina e Chirurgia "Campus Biomedico", Roma.
- 2003-2004** Istruttore, Anatomia Fisiologia e Patologia. Corso di Certificazione Regionale in Terapista Shiatsu, Siena.
- 2007-2008** Professore Aggiunto, BIO 317 General Microbiology, Temple University, Philadelphia, PA.
- 2011** Corso semestrale competitivo di Aggiornamento "College Teaching", University of Pennsylvania Center for Teaching and Learning (Prof. Catherine Turner).
- 2023** Presentatore, Master in Antibiotic Stewardship, Policlinico "Agostino Gemelli", Università Cattolica del Sacro Cuore, Roma

Studenti e Allievi (ultimi 10 ann):

Brett Slajus

University of Michigan School of Public Health, 2017-2018. Epidemiology and Prevention of MDRO Infections in nursing home residents. MPH 2018. In seguito ammesso alla Loyola University Medical School, Chicago, Illinois.

Ayesha Khanam

Laboratory identification and geographic distribution of antimicrobial resistant pathogens in Nursing Homes. Undergraduate Research opportunity Program (UROP), Class of 2019.

Isaac Kim

University of Michigan School of Public Health, 2017. Epidemiology and Prevention of MDRO Infections in Nursing Homes Residents. MPH 2018. In seguito ammesso alla SUNY Syracuse Medical School, NY.

Ziwei Zhu

University of Michigan School of Public Health, 2018. Epidemiology and Prevention of MDRO Infections in nursing homes residents. MPH 2018. In seguito assunta come Statistician Intermediate, Department of Urology, University of Michigan.

Clare Shanahan

University of Michigan School of Public Health, 2018. Impact of indwelling devices on MDRO colonization rates in nursing homes residents. MPH 2019. In seguito assunta come Infection Prevention Specialist, Henry Ford Health System, Detroit, MI.

CURRICULUM VITAE
Marco Cassone, MD, PhD

Kyle Gontjes

University of Michigan School of Public Health, 2018 and 2019. Multidrug-Resistant Organism Burden on Common Area and Rehabilitation Equipment Surfaces in Skilled Nursing Facilities. MPH 2019. In seguito ammesso a Dottorato di Ricerca, Microbiology and Immunology, University of Michigan Medical School.

Meghan Linder

University of Michigan School of Public Health, 2019. Clinical and Hospital Epidemiology Internship. Impact of roommate colonization towards MDRO acquisition in nursing home residents. MPH 2020. In seguito assunta come CSTE Applied Epidemiology Fellow, Oregon Health Authority, Eugene, OR.

Cheon Jee Shin

University of Michigan Master in Microbiology and Immunology, 2019. Patient and environmental longitudinal screening of MDROs in Skilled Nursing Facility Residents. In seguito ammessa a Dottorato di Ricerca, University of Louisville, KY.

Madison Nightingale

University of Michigan School of Public Health, 2021. Clinical and Hospital Epidemiology Internship. Analysis of healthcare workers facemask contamination burden in the SNF environment. MPH 2022. In seguito ammessa al Michigan State College of Human Medicine.

Manali Mody

University of Pittsburg, 2022. Summer Internship in Clinical and Laboratory screening of multidrug-resistant organisms in alternative care settings. Analysis of healthcare workers facemask contamination burden in the SNF environment. Class of 2026

Stephen Vear

University of Michigan School of Public Health, 2022. Research assistant. MPH 2023.

Trent Behunin

University of Michigan School of Public Health, 2022. Clinical and Hospital Epidemiology Internship. Physical disabilities and independence challenges as risk factors for MDRO colonization and adverse health outcomes. MPH 2023. In seguito assunto come Infection Preventionist, Ascension Health, Grosse Pointe, Michigan.

Morgan Harris

University of Michigan School of Public Health, 2022. Clinical and Hospital Epidemiology Internship. Epidemiology of antimicrobial resistance in methicillin-resistant staphylococci isolated from nursing home residents and their immediate environment. MPH 2023. In seguito assunta come Director, Health Insurance Analytics, New Hampshire State Department of Health.

Lana Kouatli

Michigan State University, 2023. Summer Internship in Clinical and Laboratory screening of multidrug-resistant organisms in alternative care settings. Class of 2026

Thirak Buch

Northville High School, Northville, MI, 2023. Summer Internship in Clinical and Laboratory screening of multidrug-resistant organisms in alternative care settings. Class of 2024.

CURRICULUM VITAE
Marco Cassone, MD, PhD

Alison Naif

University of Michigan School of Public Health, 2023. Clinical and Hospital Epidemiology Internship. Epidemiology and differential facility distribution of vancomycin-resistant *Enterococcus faecium* and *faecalis* in Southeast Michigan and Northeast Ohio VA Community Living Centers. MPH 2024. In seguito assunta come Infection Preventionist, Detroit Medical Center, Detroit, Michigan.

BIBLIOGRAFIA

Publicazioni soggette a peer review

1. Carfagna, P., Cattaneo, M., **Cassone, M.**, Serra, P. Peripheral embolic events from myocardial thrombosis in a young man with hyperhomocysteinemia [Embolie periferiche da trombosi endocardica in un giovane con iperomocisteinemia]. (1997) *Annali Italiani di Medicina Interna*, 12 (3), pp. 173-175.
2. Venditti, M., Brandimarte, C., Capone, A., **Cassone, M.**, Galie, M., Tarasi, A., Tarasi, D. Endocarditis caused by *Enterococcus faecalis* with high-level resistance to aminoglycosides: Failure of ampicillin and ceftriaxone combined therapy. (1997) *Clinical Microbiology and Infection*, 3 (5), pp. 577-580.
3. Galie, M., **Cassone, M.**, Ausiello, C., Serra, P. Idiopathic CD4+ T lymphocytopenia: Clinical evolution of a case [Deficit idiopatico di linfociti T CD4+: Evoluzione clinica di un caso]. (1997) *Annali Italiani di Medicina Interna*, 12 (4), pp. 233-237.
4. Baiocchi, P., Galiè, M., Santini, C., Carfagna, P., **Cassone, M.**, Tarasi, D., Venditti, M. In vitro susceptibility of *Staphylococcus aureus* isolated from blood to currently used antistaphylococcal drugs. (1998) *Journal of Chemotherapy*, 10 (1), pp. 25-28.
5. Capone, A., **Cassone, M.**, Tarasi, D., Brandimarte, C., Tarasi, A., Galiè, M., Venditti, M. Fatal suppurative mesenteric thrombophlebitis caused by an *Enterococcus faecalis* highly resistant to aminoglycosides: Case report. (1998) *Journal of Chemotherapy*, 10 (2), pp. 128-131.
6. Tarasi, A., Capone, A., Tarasi, D., **Cassone, M.**, Bianco, G., Venditti, M. Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis. (1999) *Journal of Antimicrobial Chemotherapy*, 43 (6), pp. 833-835.
7. Carfagna, P., Tarasi, A., **Cassone, M.**, Del Grosso, M.F., Bianco, G., Venditti, M. Prosthetic biologic valve endocarditis caused by a vancomycin-resistant (*vanA*) *Enterococcus faecalis*: Case report. (2000) *Journal of Chemotherapy*, 12 (5), pp. 416-420.
8. Venditti, M., **Cassone, M.**, Falcone, M., Pavoni, G., Pistella, E., Paris, A. Role of piperacillin-tazobactam in the treatment of nosocomial infections [Piperacillina-tazobactam nel

CURRICULUM VITAE
Marco Cassone, MD, PhD

trattamento delle infezioni gravi nosocomiali]. (2002) *Recenti Progressi in Medicina*, 93 (3), pp. 200-211.

9. Claudio, S., Berton, E., Galiè, M., **Cassone, M.**, Vitelli, C., Serra, P., Venditti, M. Tuberculous lymphadenitis at the hepatic hilum with portal thrombosis in an immunocompetent patient. (2002) *Infectious Diseases in Clinical Practice*, 11 (4), pp. 214-218.
10. Falcone, M., Carfagna, P., **Cassone, M.**, Pistella, E., Pavoni, G., Nofroni, I., Serra, P., Venditti, M. Staphylococcus aureus sepsis in hospitalized non neutropenic patients: retrospective clinical and microbiological analysis [Sepsi da Staphylococcus aureus in pazienti ospedalizzati non neutropenici: analisi retrospettiva clinica e microbiologica.]. (2002) *Annali Italiani di Medicina Interna*, 17 (3), pp. 166-172.
11. Pavoni, G.L., Falcone, M., Baiocchi, P., Tarasi, A., **Cassone, M.**, Serra, P., Venditti, M. Conservative medical therapy of infections following osteosynthesis: A retrospective analysis of a six-year experience. (2002) *Journal of Chemotherapy*, 14 (4), pp. 378-383.
12. Tarasi, A., **Cassone, M.**, Monaco, M., Tarasi, D., Pompeo, M.E., Venditti, M. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. (2003) *Journal of Chemotherapy*, 15 (3), pp. 239-243.
13. **Cassone, M.**, Serra, P., Mondello, F., Girolamo, A., Scafetti, S., Pistella, E., Venditti, M. Outbreak of Saccharomyces cerevisiae Subtype boulardii Fungemia in Patients Neighboring Those Treated with a Probiotic Preparation of the Organism. (2003) *Journal of Clinical Microbiology*, 41 (11), pp. 5340-5343.
14. **Cassone, M.**, Campanile, F., Pantosti, A., Venditti, M., Stefani, S. Identification of a Variant "Rome Clone" of Methicillin-Resistant Staphylococcus aureus with Decreased Susceptibility to Vancomycin, Responsible for an Outbreak in an Intensive Care Unit. (2004) *Microbial Drug Resistance*, 10 (1), pp. 43-49.
15. **Cassone, M.**, D'Andrea, M.M., Iannelli, F., Oggioni, M.R., Rossolini, G.M., Pozzi, G. DNA microarray for detection of macrolide resistance genes. (2006) *Antimicrobial Agents and Chemotherapy*, 50 (6), pp. 2038-2041.
16. Oggioni, M.R., Trappetti, C., Kadioglu, A., **Cassone, M.**, Iannelli, F., Ricci, S., Andrew, P.W., Pozzi, G. Switch from planktonic to sessile life: A major event in pneumococcal pathogenesis.(2006) *Molecular Microbiology*, 61 (5), pp. 1196-1210.

CURRICULUM VITAE
Marco Cassone, MD, PhD

17. Trani, D., Lucchetti, C., **Cassone, M.**, D'Agostino, L., Caputi, M., Giordano, A. Analysis of cell-cycle regulation following exposure of lung-derived cells to γ -rays. (2007) *Advances in Space Research*, 39 (6), pp. 1026-1033.
18. **Cassone, M.**, Del Grosso, M., Pantosti, A., Giordano, A., Pozzi, G. Detection of genetic elements carrying glycopeptide resistance clusters in *Enterococcus* by DNA microarrays. (2008) *Molecular and Cellular Probes*, 22 (3), pp. 162-167.
19. Noto, P.B., Abbadessa, G., **Cassone, M.**, Mateo, G.D., Agelan, A., Wade, J.D., Szabo, D., Kocsis, B., Nagy, K., Rozgonyi, F., Otvos Jr., L. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. (2008) *Protein Science*, 17 (7), pp. 1249-1255.
20. Otvos Jr., L., Terrasi, M., Cascio, S., **Cassone, M.**, Abbadessa, G., De Pascali, F., Scolaro, L., Knappe, D., Stawikowski, M., Cudic, P., Wade, J.D., Hoffmann, R., Surmacz, E. Development of a pharmacologically improved peptide agonist of the leptin receptor. (2008) *Biochimica et Biophysica Acta - Molecular Cell Research*, 1783 (10), pp. 1745-1754.
21. **Cassone, M.**, Vogiatzi, P., La Montagna, R., De Olivier Inacio, V., Cudic, P., Wade, J.D., Otvos Jr., L. Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics. (2008) *Peptides*, 29 (11), pp. 1878-1886.
22. **Cassone, M.**, Frith, N., Vogiatzi, P., Wade, J.D., Otvos Jr., L. Induced resistance to the designer proline-rich antimicrobial peptide A3-APO does not involve changes in the intracellular target DnaK. (2009) *International Journal of Peptide Research and Therapeutics*, 15 (2), pp. 121-128.
23. Otvos Jr., L., **Cassone, M.**, Inacio, V.O., Noto, P., Rux, J.J., Wade, J.D., Cudic, P. Synergy between a lead proline-rich antibacterial peptide derivative and small molecule antibiotics. (2009) *Advances in experimental medicine and biology*, 611, pp. 375-378.
24. Otvos Jr., L., **Cassone, M.**, Terrasi, M., Cascio, S., Mateo, G.D., Knappe, D., Hoffmann, R., Cudic, P., Wade, J.D., Surmacz, E. Agonists and partial antagonists acting on the leptin--leptin receptor interface. (2009) *Advances in experimental medicine and biology*, 611, pp. 497-498.
25. Rozgonyi, F., Szabo, D., Kocsis, B., Ostorházi, E., Abbadessa, G., **Cassone, M.**, Wade, J.D., Otvos Jr., L. The antibacterial effect of the proline-rich antibacterial peptide A3-APO. (2009) *Current Medicinal Chemistry*, 16 (30), pp. 3996-4002.
26. Szabo, D., Ostorhazi, E., Binas, A., Rozgonyi, F., Kocsis, B., **Cassone, M.**, Wade, J.D., Nolte, O., Otvos Jr., L. The designer proline-rich antibacterial peptide A3-APO is effective against systemic *Escherichia coli* infections in different mouse models. (2010) *International Journal of Antimicrobial Agents*, 35 (4), pp. 357-361.

CURRICULUM VITAE
Marco Cassone, MD, PhD

27. Kovalszky, I., Surmacz, E., Scolaro, L., **Cassone, M.**, Ferla, R., Sztodola, A., Olah, J., Hatfield, M.P.D., Lovas, S., Otvos, L. Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models. (2010) *Diabetes, Obesity and Metabolism*, 12 (5), pp. 393-402.
28. Ostorhazi, E., Rozgonyi, F., Sztodola, A., Harnos, F., Kovalszky, I., Szabo, D., Knappe, D., Hoffmann, R., **Cassone, M.**, Wade, J.D., Bonomo, R.A., Otvos Jr., L. Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in *Acinetobacter baumannii* wound infections. (2010) *Journal of Antimicrobial Chemotherapy*, 65 (11), pp. 2416-2422.
29. Ostorhazi, E., Rozgonyi, F., Szabo, D., Binas, A., **Cassone, M.**, Wade, J.D., Nolte, O., Bethel, C.R., Bonomo, R.A., Otvos Jr., L. Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant *Acinetobacter baumannii* in mouse models of systemic infections. (2011) *Biopolymers*, 96 (2), pp. 126-129.
30. Otvos Jr., L., Kovalszky, I., Scolaro, L., Sztodola, A., Olah, J., **Cassone, M.**, Knappe, D., Hoffmann, R., Lovas, S., Hatfield, M.P.D., Beko, G., Zhang, S., Wade, J.D., Surmacz, E. Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation. (2011) *Biopolymers*, 96 (2), pp. 117-125.
31. Ostorhazi, E., Holub, M.C., Rozgonyi, F., Harnos, F., **Cassone, M.**, Wade, J.D., Otvos Jr., L. Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved. (2011) *International Journal of Antimicrobial Agents*, 37 (5), pp. 480-484.
32. Otvos, L., Haspinger, E., LaRussa, F., Maspero, F., Graziano, P., Kovalszky, I., Lovas, S., Nama, K., Hoffmann, R., Knappe, D., **Cassone, M.**, Wade, J., Surmacz, E. Design and Development of a Peptide-based Adiponectin Receptor Agonist for Cancer Treatment. (2011) *BMC Biotechnology*, 11, 90.
33. **Cassone, M.**, Gagne, A.L., Spruce, L.A., Seeholzer, S.H., Sebert, M.E. The HtrA protease from *Streptococcus pneumoniae* digests both denatured proteins and the competence-stimulating peptide. (2012) *Journal of Biological Chemistry*, 287 (46), pp. 38449-38459.
34. Gagne, A.L., Stevens, K.E., **Cassone, M.**, Pujari, A., Abiola, O.E., Chang, D.J., Sebert, M.E. Competence in *Streptococcus pneumoniae* Is a Response to an Increasing Mutational Burden. (2013) *PLoS ONE*, 8 (8), art. no. e7261
35. Knappe, D., **Cassone, M.**, Nollmann, F.I., Otvos Jr., L., Hoffmann, R. Hydroxyproline substitutions stabilize non-glycosylated drosocin against serum proteases without challenging its antibacterial activity. (2014) *Protein and Peptide Letters*, 21 (4), pp. 321-329.

CURRICULUM VITAE
Marco Cassone, MD, PhD

36. Gibson, KE., McNamara, SE., **Cassone, M.**, Perri, MB., Zervos, M., Mody, L. Methicillin-resistant *Staphylococcus aureus*: site of acquisition and strain variation in high-risk nursing home residents with indwelling devices. (2014) *Infect Control Hosp Epidemiol*, 35 (12), pp. 1458-65.
37. **Cassone, M.**, McNamara, SE., Perri, MB., Zervos, M., Mody, L. Impact of intervention measures on MRSA clonal type and carriage site prevalence. (2016) *mBio*, 7 (2), p. e00218.
38. Iannelli F, Santoro F, Santagati M, Docquier JD, Lazzeri E, Pastore G, **Cassone M**, Oggioni MR, Rossolini GM, Stefani S, Pozzi G. Type M Resistance to Macrolides is Due to a Two-Gene Efflux Transport System of the ATP-Binding Cassette (ABC) Superfamily. (2018) *Front Microbiol*, 31 (9), pp e1670.
39. Mody, L., Foxman, B., Bradley, S., McNamara, SE., Lansing, BJ., Gibson, KE., **Cassone, M.**, Armbruster, C., Mantey, J., Min, L. Longitudinal assessment of multidrug-resistant organisms (MDROs) in newly-admitted nursing facility patients: implications for an evolving population. (2018) *Clin Infect Dis*, 67 (6), pp 837-44.
40. **Cassone, M.**, Mantey, J., Perri, MB., Gibson, KE., Lansing, BJ., McNamara, SE., Patel, PK., Cheng, VCC., Walters, MS., Stone, ND., Zervos, M., Mody, L. Environmental panels as a proxy for nursing facility patients with MRSA and VRE colonization. (2018) *Clin Infect Dis*, 67 (6), pp 861-8.
41. Heinze K, Kabeto M, Toth Martin E, **Cassone M**, Hicks L, Mody L. Predictors of methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci co-colonization among nursing facility patients. (2019) *Am J Infect Control*, 47(4), pp 415-20
42. Mantey J, Min L, **Cassone M**, Gibson KE, Mody L. Changing dynamics of colonization in nursing facility patients over time: reduction in MRSA offset by increase in VRE prevalence. (2019) *Infect Control Hosp Epidemiol*, 40(9), pp 1069-70
43. Mills JP, Zhu Z, Mantey J, Hatt S, Patel P, Kaye KS, Gibson KE, **Cassone M**, Lansing BJ, Mody L. The devil is in the details: factors influencing hand hygiene adherence and contamination with antimicrobial-resistant organisms among healthcare providers in nursing facilities. (2019) *Infect Control Hosp Epidemiol*, 40(12), pp 1394-99
44. Libertucci J, Bassis CM, **Cassone M**, Gibson KE, Lansing BJ, Mody L, Young VB, Meddings J. Bacteria detected in both urine and open wounds in nursing home residents: a pilot study. (2019) *mSphere* 4(4). pii: e00463-19
45. Mody L, Washer LL, Kaye KS, Gibson K, Saint S, Reyes K, **Cassone M**, Mantey J, Cao J, Altamimi S, Perri M, Sax H, Chopra V, Zervos M. Multidrug-resistant organisms in hospitals: what is on patient hands and in their rooms? (2019) *Clin Infect Dis*, 69(11), pp 1837-44

CURRICULUM VITAE
Marco Cassone, MD, PhD

46. **Cassone M**, Zhu Z, Mantey J, Gibson KE, Lansing BJ, Perri MB, Zervos MJ, Snitkin ES, Foxman B, Mody L. Interplay Between Patient Colonization and Environmental Contamination with Vancomycin-Resistant Enterococci, and Their Association with Patient Health Outcomes in Post-Acute Care. (2019) *Open Forum Inf Dis* 7(1), pp ofz519
47. Gontjes K, Gibson KE, Lansing BJ, **Cassone M**, Mody L. Contamination of Common Area and Rehabilitation Gym Environment with Multidrug-Resistant Organisms. (2020) *JAGS* 68(3), pp 478-85
48. Davis E, Hicks L, Ali I, Salzmann E, Wang J, Snitkin ES, Gibson KE, **Cassone M**, Mody L, Foxman B. Epidemiology of vancomycin-resistant *Enterococcus faecium* and *Enterococcus faecalis* colonization in nursing facilities. (2020) *Open Forum Inf Dis* 7(1), pp ofz553
49. Wang J, **Cassone M**, Gibson K, Lansing B, Mody L, Snitkin ES, Rao K. Gut Microbiota Features on Nursing Home Admission Are Associated With Subsequent Acquisition of Antibiotic-resistant Organism Colonization. (2020) *Clin Infect Dis*. Dec 15;71(12):3244-3247
50. Gontjes KJ, Gibson KE, Lansing BJ, Mody L, **Cassone M**. Assessment of Race and Sex as Risk Factors for Colonization with Multidrug-Resistant Organisms in Six Nursing Homes. (2020) *Infect Control Hosp Epidemiol*. Oct;41(10):1222-1224
51. Mody L, Gontjes KJ, **Cassone M**, Gibson KE, Lansing BJ, Mantey J, Kabeto M, Galecki A, Min L. Effectiveness of a Multicomponent Intervention to Reduce Multidrug-Resistant Organisms in Nursing Homes: A Cluster Randomized Clinical Trial. *JAMA Netw Open*. 2021;4(7):e2116555.
52. **Cassone M**, Mody L. Measuring the outsized impact of COVID-19 in the evolving setting of aged care facilities. (2021) *EClinicalMedicine*. Apr;34:100825.
53. **Cassone M**, Mantey J, Gontjes KJ, Lansing B, Gibson KE, Wang J, Mody L. Seasonal Patterns in Incidence and Antimicrobial Resistance of Common Bacterial Pathogens in Nursing Home Patients and Their Rooms. (2021) *Front Public Health*. 9: 959.
54. **Cassone M**, Linder M, Shin CJ, Mantey J, Gibson K, Lansing B, Mody L. Not too close! impact of roommate status on MRSA and VRE colonization and contamination in Nursing Homes. (2021) *Antimicrob Resist Infect Control*. Jul 5;10(1):104.
55. **Cassone M**, Mody L. To each villain its plot: the case of *Candida auris*. (2021) *Annals Int Med* Sep 7. doi: 10.7326/M21-3456.
56. Gibson KE, Mills JP, Mantey JA, Lansing BJ, **Cassone M**, Mody L. Multidrug-resistant organism (MDRO) contamination of privacy curtains in nursing homes. (2022) *Infect Control Hosp Epidemiol*. 43(5):666-68.

CURRICULUM VITAE
Marco Cassone, MD, PhD

57. Gontjes KJ, Gibson KE, Lansing B, **Cassone M**, Mody L. Can alternative anatomical sites and environmental surveillance replace perianal screening for multidrug-resistant organisms in nursing homes? (2022) *Infect Control Hosp Epidemiol.* 43(8):1063-66.
58. Wolfensberger A, Mang N, Gibson KE, Gontjes K, **Cassone M**, Brugger SD, Mody L, Sax H. Understanding short-term transmission dynamics of methicillin-resistant *Staphylococcus aureus* in the patient room. (2022). *Infect Control Hosp Epidemiol*, 43(9):1147-54.
59. Gontjes, K. J., Gibson, K. E., Lansing, B. J., Mantey, J., Jones, K. M., **Cassone, M.**, Wang, J., Mills, J. P., Mody, L., & Patel, P. K. (2022). Association of Exposure to High-risk Antibiotics in Acute Care Hospitals With Multidrug-Resistant Organism Burden in Nursing Homes. *JAMA network open*, 5(2), e2144959.
60. Mody, L., Gibson, K. E., Mantey, J., Bautista, L., Montoya, A., Neeb, K., Jenq, G., Mills, J. P., Min, L., Kabeto, M., Galecki, A., **Cassone, M.**, & Martin, E. T. (2022). Environmental contamination with SARS-CoV-2 in nursing homes. *Journal of the American Geriatrics Society*, 70(1), 29–39.
61. Mills JP, Mantey J, **Cassone M**, Kaye KS, Mody L. (2023). Epidemiology of resistant gram-negative bacteria in nursing homes. *Infect Control Hosp Epidemiol.* 14(3), 1-6.
62. Nightingale M, Mody M, Rickard AH, **Cassone M**. (2023). Bacterial Contamination on Used Face Masks in Nursing Home Healthcare Personnel. *Antimicrob Steward Healthc Epidemiol*, 3(1), e54.
63. **Cassone M**, Wang J, Lansing BJ, Mantey J, Gibson KE, Gontjes KJ, Mody L. (2023). Diversity and Persistence of MRSA and VRE in Skilled Nursing Facilities: Environmental Screening, Whole Genome Sequencing, Development of a Dispersion Index. *The Journal of Hospital Infection*, S0195-6701(23)00140-8.
64. Wang J, Foxman B, Rao K, **Cassone M**, Gibson K, Mody L, Snitkin ES. Association of patient clinical and gut microbiota features with vancomycin-resistant enterococci environmental contamination in nursing homes: a retrospective observational study. *Lancet Healthy Longev.* 2023 Nov;4(11):e600-e607.
65. **Cassone M**, Ameling J, Mody L, Patel S, Muyanja N, Meddings J. Impact of External Female Urinary Catheter Use on Urine Chemistry Test Results. *Am J Infect.* 2024 May 10; 1-6 *online ahead of print*
66. Behunin T, Vijayasiri G, Gibson KE, Mody L, **Cassone M**. (2024) Functional Dependence as a Contributing Factor for Patient Hand Contamination by Multi-Drug Resistant Organisms (MDROs) in Acute Care. *Infect Control Hosp Epidemiol.* 2024; 27:S0196-6553(24)00134-2 *online ahead of print*
67. Mody L, Gibson KE, **Cassone M**, Vijayasiri G, Snitkin ES, Saint S, Krein S, Janevic MJ, Thiel J, Ridenour J, Nguyen A, Hicks O, Bej T, El Chakhtoura N, Min L, Galecki A, Greene T, Roghmann MC, Chigurupati L, Perez F, Jump RL (2025). Epidemiology of Multidrug-Resistant Organisms (MDROs) Across Three

CURRICULUM VITAE
Marco Cassone, MD, PhD

VA Nursing Homes and MDRO Transmission During Interactive Visits. *Nature communications*. 2025; *in press*

Capitoli in Libri

Montoya, A., **Cassone, M.**, Mody, L. Infections in Nursing Homes: Epidemiology and Prevention Programs. (2016) *Clin Geriatr Med*, 32 (3), pp. 585-607.

Sturm L, Flood M, Montoya A, Mody L, **Cassone M.** Updates on Infection control in alternative care settings. (2021) *Infect Dis Clin North Am*. Sep;35(3):803-825. doi: 10.1016/j.idc.2021.04.013.

Presentazioni a Conferenze (selezione parziale)

Gibson KE, Vijayasiri G, **Cassone M**, Mody L. Comparing the predictive value of environmental surfaces screening for assessment of patient colonisation: VA-community living centres vs non-VA nursing homes. ECCMID 2024, Barcelona, Spain

Naif A, Gibson KE, Mody L, **Cassone M**. Variation in Vancomycin Resistant *Enterococcus faecalis* and *faecium* prevalence and ratio in VA Community Living Centers. AGS 2024.

Saab M, Hua H, Vijayasiri G, **Cassone M**. Predictors of Multidrug-Resistant Organisms (MDRO) contamination in nursing homes: focus on sex and diabetes mellitus. AGS 2024.

Behunin T, Mantey J, **Cassone M**, Mody L. Functional Dependence as a Contributing Factor for Patient Hand Contamination by Multi-Drug Resistant Organisms in Acute Care. SHEA Spring 2023, Seattle, WA

Harris M, Gibson KE, **Cassone M**. Antibiotic Resistance Profiles of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Isolates Recovered in Post-acute Care Screening of Patients and Environmental Surfaces. AGS 2023, Long Beach, CA

Cassone M, Lansing B, Mantey J, Gibson KE, Gontjes KJ, Mody L. Diversity and Persistence of MRSA and VRE in Nursing Homes: Environmental Screening and Whole Genome Sequencing. Oral Abstract 166. SHEA Spring 2022, Colorado Springs, CO

Nightingale M, Mody M, Rickard A, **Cassone M**. Bacterial Contamination on Used Face Masks in Healthcare Personnel. Oral Abstract 172. SHEA Spring 2022, Colorado Springs, CO

CURRICULUM VITAE
Marco Cassone, MD, PhD

Cassone M, Lansing B, Mantey J, Gibson KE, Gontjes KJ, Mody L. Impact of Hand Hygiene Assistance and Room Occupancy Changes in Persistence of Multidrug-Resistant Organisms in Nursing Homes. AGS 2022, Orlando, FL

Cassone M, Ameling J, Mody L, Meddings J. Impact of External Female Urinary Catheter Use on Routine Urine Test Results. AGS 2022, Orlando, FL

Linder M, Shin CJ, Gibson K, Lansing B, Mody L, **Cassone M**. Not too close! Impact of Roommate Status on MRSA and VRE Colonization and Contamination in Skilled Nursing Facilities. Abstract 5757. ASM Microbe 2020, Chicago, IL.

Cassone M, Mantey J, Gontjes K, Lansing B, Gibson K, Mody L. Seasonal patterns in the burden of common bacterial pathogens in south-east Michigan post-acute care facilities. Abstract 7629. ECCMID 2020, Paris, France.

Wolfsberger A, Mang N, **Cassone M**, Gontjes K, Gibson K, Sax H, Mody L. Short-term environmental contamination with MRSA explained by in-room activity of MRSA-colonised patients. Abstract 2441. ECCMID 2020, Paris, France.

Wang J, **Cassone M**, Gibson KE, Lansing BJ, Mody L, Snitkin ES, Rao K. Antibiotic-Resistant Organism Acquisition in Nursing Facility Patients. ATCS Meeting 2020, Washington, DC.

Cassone M, Ziwei Zhu, Kristen E Gibson, Bonnie J Lansing, Jie Cao, Lona Mody. *Acinetobacter baumannii* in the post-acute care setting: prevalence and resistance rates in patients, health care personnel and the environment. IDWeek 2018, San Francisco, CA.

Cassone M, Mantey J, Gibson KE, Zhu Z, Mody L. A safe place for grandma? Environmental contamination as a risk factor for MRSA and VRE colonization and adverse health outcomes in long-term care. ECCMID 2018, Madrid, Spain. Oral presentation

Davis E, Hicks L, Ali I, Salzman E, Wang J, Snitkin E, **Cassone M**, Mody L, Foxman B. Vancomycin resistant enterococcus (VRE) prevalence, incidence, and duration of carriage among nursing home residents. American College of Epidemiology 2018 Meeting, Cincinnati, OH

Cassone M, Armbruster C, Snitkin E, Gibson K, Mantey J, Reyes K, Altamimi S, Perri MB, Zervos M, Mody L. Relatedness of MRSA and VRE strains isolated from post-acute care patients and their environment: a longitudinal assessment. IDWeek 2017, San Diego, CA.

Cassone M, Mantey J, McNamara S, Gibson K, Lansing B, Mody L. Predictive value of environmental sites panels as a proxy for Nursing Home resident MRSA and VRE colonization. Society of Healthcare epidemiology of America (SHEA) symposium 2017, St. Louis, MO. Best poster award

Cao J, McNamara S, Lansing B, Gibson K, Koo E, **Cassone M**, Mody L. MDROs on resident hands: should we refrain from shaking hands? Presidential Award Poster Session. American Geriatrics Society (AGS) Meeting, 2015, National Harbor, MD.

CURRICULUM VITAE
Marco Cassone, MD, PhD

Gibson KE, McNamara SE, **Cassone M**, Perri MB, Zervos M, Mody L. Methicillin-resistant *Staphylococcus aureus*: site of acquisition and strain variation in high-risk nursing home residents. American Geriatrics Society (AGS) Meeting, 2014, Orlando, FL

Cassone M, Sebert ME. Degradation of the pneumococcal competence-stimulating peptide by the bacterial HtrA protease. 112TH American Society of Microbiology (ASM) Meeting, 2012, San Francisco, CA.

Cassone M, Rozgonyi F, Szabo D, Kocsis B, Vogiatzi P, Otvos L, Jr. Study of in vivo Efficacy and Resistance Induction Potential of the Proline-rich Antimicrobial Peptide Dimer A3-APO and its Single Chain Metabolite. 109TH American Society of Microbiology (ASM) Meeting, 2009, Philadelphia, PA.

Cassone M, Vogiatzi P, Wade JD, Rozgonyi F, Szabo D, Kocsis B, Otvos L Jr. The Proline-Rich antimicrobial peptide dimer A3-APO and its single chain in vivo metabolite represent a new paradigm in microbiology, pharmacology and drug development. 30th European Peptide Symposium (EPS), 2008, Helsinki, Finland. Oral presentation

Otvos L Jr, **Cassone M**, Noto P, Abbadessa G, Vogiatzi P, Wade JD, Cudic P, Inacio VDO, Szabo D, Kocsis B and Rozgonyi F. The long and winding road to antibacterial peptides effective in systemic infection models. PUG 2008, Melbourne, Australia

Otvos L Jr, **Cassone M**, Inacio VDO, Noto P, Rux JJ, Wade JD, Cudic P. Synergy between a lead proline-rich antibacterial peptide derivative and small molecule antibiotics. 20th American Peptide Society (APS) Symposium, 2007, Montreal, Canada

Cassone M, D'Andrea MM, Iannelli F, Oggioni MR, Rossolini GM, Pozzi G. Development of DNA Microarrays to detect macrolide resistance genes. ECCMID 2004, Praha, Czech Republic. Oral presentation

Iannelli E, Santagati M, Docquier JD, **Cassone M**, Oggioni MR, Rossolini GM, Stefani S, Pozzi G. Type M Resistance to Macrolides in *Streptococci* is not due to the *mef(A)* gene, but to *mat(A)* encoding an ATP-dependent efflux pump. ICAAC 2004, Washington, DC.

Oggioni MR, Iannelli F, Ricci S, Chiavolini D, Parigi R, **Cassone M**, Claverys J, Pozzi G. Antibacterial activity of the Competence Stimulating Peptide in experimental sepsis by *Streptococcus pneumoniae*. ICAAC 2004, Washington, DC.

Cassone M, Scafetti S, Mondello F, Pavoni G, Venditti M. *S.boulardii* fungemia in three Intensive Care Unit patients not receiving *S. boulardii* therapy. ECCMID 2002, Milan, Italy